|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
68,990,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Bicycle Therapeutics is a holding company. Through its subsidiaries, Co. is a clinical-stage biopharmaceutical company developing a class of medicines, which it refers to as Bicycles. Bicycles are a therapeutic modality combining the pharmacology associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. Co. is evaluating BT5528, a Bicycle Toxin Conjugate (BTC) targeting Ephrin type-A receptor 2, BT8009, a BTC targeting Nectin-4, and BT7480, a Bicycle tumor-targeted immune cell agonist® targeting Nectin-4 and agonizing CD137. In addition, BT1718, a BTC that is being developed to target tumors that express Membrane Type 1 matrix metalloproteinase.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
7,268 |
14,490 |
37,488 |
61,094 |
Total Sell Value |
$142,744 |
$314,362 |
$724,634 |
$1,369,761 |
Total People Sold |
7 |
7 |
7 |
9 |
Total Sell Transactions |
7 |
14 |
26 |
45 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Lee Kevin |
Chief Executive Officer |
|
2021-07-16 |
4 |
OE |
$14.00 |
$8,526 |
D/D |
609 |
245,694 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2021-07-15 |
4 |
AS |
$34.28 |
$753,132 |
D/D |
(21,970) |
245,085 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2021-07-15 |
4 |
OE |
$14.00 |
$307,580 |
D/D |
21,970 |
267,055 |
|
- |
|
Keen Nicholas |
Chief Scientific Officer |
|
2021-07-14 |
4 |
AS |
$35.00 |
$350,000 |
D/D |
(10,000) |
18,321 |
|
- |
|
Bingham Kate |
Director |
|
2021-07-14 |
4 |
AS |
$34.01 |
$1,506,367 |
I/I |
(44,295) |
38,708 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2021-07-14 |
4 |
AS |
$32.93 |
$496,726 |
D/D |
(14,465) |
245,085 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2021-07-14 |
4 |
OE |
$14.00 |
$116,634 |
D/D |
8,331 |
259,550 |
|
- |
|
Bingham Kate |
Director |
|
2021-07-13 |
4 |
AS |
$33.50 |
$20,100 |
I/I |
(600) |
39,625 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2021-07-13 |
4 |
AS |
$32.42 |
$1,284,680 |
D/D |
(38,961) |
251,219 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2021-07-13 |
4 |
OE |
$14.00 |
$496,244 |
D/D |
35,446 |
290,180 |
|
- |
|
Crockett Nigel |
Chief Business Officer |
|
2021-07-13 |
4 |
AS |
$32.41 |
$2,358,362 |
D/D |
(72,701) |
0 |
|
- |
|
Crockett Nigel |
Chief Business Officer |
|
2021-07-13 |
4 |
OE |
$9.82 |
$860,433 |
D/D |
72,701 |
72,701 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2021-07-12 |
4 |
AS |
$32.04 |
$62,029 |
D/D |
(1,936) |
254,734 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2021-07-12 |
4 |
OE |
$14.00 |
$27,104 |
D/D |
1,936 |
256,670 |
|
- |
|
Crockett Nigel |
Chief Business Officer |
|
2021-07-12 |
4 |
AS |
$32.03 |
$225,107 |
D/D |
(7,028) |
0 |
|
- |
|
Crockett Nigel |
Chief Business Officer |
|
2021-07-12 |
4 |
OE |
$9.82 |
$82,380 |
D/D |
7,028 |
7,028 |
|
- |
|
Crockett Nigel |
Chief Business Officer |
|
2021-07-06 |
4 |
AS |
$32.00 |
$8,672 |
D/D |
(271) |
0 |
|
- |
|
Crockett Nigel |
Chief Business Officer |
|
2021-07-06 |
4 |
OE |
$9.82 |
$2,661 |
D/D |
271 |
271 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2021-05-07 |
4 |
AS |
$32.23 |
$180,617 |
D/D |
(5,604) |
254,734 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2021-05-07 |
4 |
OE |
$14.00 |
$78,456 |
D/D |
5,604 |
260,338 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2021-05-06 |
4 |
AS |
$32.14 |
$55,152 |
D/D |
(1,716) |
254,734 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2021-05-06 |
4 |
OE |
$14.00 |
$24,024 |
D/D |
1,716 |
256,450 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2021-05-04 |
4 |
AS |
$32.03 |
$28,731 |
D/D |
(897) |
254,734 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2021-05-04 |
4 |
OE |
$14.00 |
$12,558 |
D/D |
897 |
255,631 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2021-05-03 |
4 |
AS |
$32.16 |
$109,055 |
D/D |
(3,391) |
254,734 |
|
- |
|
226 Records found
|
|
Page 6 of 10 |
|
|